Abstract
Hypoxia, abnormal perfusion, and oncogenic signaling increase lactate production in lung cancer and create intercellular fluxes mediated by monocarboxylate transporters. Circulating lactate can be taken up by lung tumors and enter the tricarboxylic acid (TCA) cycle. Lactate therefore acts as a carbon source, a regulator of redox and acid-base homeostasis, and a precursor for lysine L-lactylation. Representative validated modifications include histone H3 lysine 18 lactylation (H3K18la) and histone H4 lysine 5 lactylation (H4K5la) together with nonhistone substrates such as programmed death ligand 1 (PD-L1), hexokinase 2 (HK2), mitochondrial cristae-organizing protein Mic60, and replication protein A1 (RPA1), linking lactylation to transcriptional regulation, protein stability, metabolic adaptation, immune evasion, DNA repair, and treatment resistance in lung cancer. Tumor-derived lactate also reprograms cluster of differentiation 8-positive (CD8+) T cells, regulatory T cells, macrophages, dendritic cells, and cancer-associated fibroblasts across hypoxic cores, invasive fronts, perivascular regions, and tertiary lymphoid structure-associated areas. This review integrates lactate-pool formation, lactylation writers and erasers, intracellular reprogramming, immune-stromal interactions, and spatial niches. It distinguishes metabolic and acidification effects of lactate from covalent lactylation and separates direct causal evidence in lung cancer from spatial associations and cross-cancer mechanistic support. This framework defines a source-to-site chain for studying regional lactate activity and lactylation-dependent phenotypes in lung cancer.
1 Introduction
Intraoperative stable isotope tracing of human lung tumors has demonstrated marked variation in glucose oxidation and tricarboxylic acid (TCA) cycle activity among patients and across regions of the same tumor (). Accordingly, lung cancer metabolism cannot be reduced to a single high-glycolysis phenotype; it is also necessary to explain how substrates move among cell types and tissue regions. Lactate can function simultaneously as a transferable carbon source, a product of glycolytic metabolism, and a mediator of proton-coupled microenvironmental stress (ā). The actions of lactate in lung cancer therefore encompass at least three interconnected but noninterchangeable levels: lactate as a metabolic substrate, acidification caused by lactate-proton cotransport, and lactylation arising from the covalent attachment of a lactyl group to lysine.
The discovery of histone lactylation in 2019 established a direct connection between lactate metabolism and chromatin regulation (). Subsequent studies expanded the range of lactylated substrates from histones to transcription factors, metabolic enzymes, DNA-repair proteins, RNA-modifying proteins, and immune-checkpoint molecules. Site-specific studies in lung cancer now show that histone and nonhistone lactylation can convert altered lactate metabolism into persistent transcriptional and protein-level phenotypes (). These findings indicate that transient fluctuations in lactate can be converted into sustained immune-evasive or adaptive phenotypes through regulation of chromatin and protein stability. Here, lactylation writers install lactyl groups on protein substrates, and erasers remove them.
The effects of lactate and lactylation are also strongly conditioned by spatial context. Hypoxic, perfused, stromal-rich, and immune-rich regions can differ in lactate source and recipient cells, and spatial multiomics in lung adenocarcinoma has linked lactate status with epithelial, fibroblast, angiogenic, and immunosuppressive programs (). However, spatial association alone does not establish directional lactate transfer or site-specific lactylation.
Because hypoxic and well-perfused regions can differ in lactate export and oxidation (), static tissue lactate measurements cannot by themselves define source or fate; mechanistic interpretation requires directional flux and cell- and site-specific validation. Accordingly, this review uses a source-to-site framework to connect lactate origin and transport with lactylation, cellular phenotype, and spatial architecture. It prioritizes site-level and functional evidence from lung cancer, uses spatial and clinical studies to define tissue relevance, and treats mechanistic findings from other tumors as supportive rather than definitive.
2 Lactate sources and lactylation evidence
Lactylation lies downstream of lactate metabolism, yet an increase in cellular lactate does not necessarily induce synchronous lactylation at every protein site.
2.1 Pulmonary lesion lactate pools
Within pulmonary lesions, hypoxia and increased glycolytic flux can expand the local lactate pool through lactate dehydrogenase (LDH)-dependent pyruvate-to-lactate conversion. A study using isomer-specific antibodies and quantitative mass spectrometry found that hypoxia markedly increased nuclear lysine L-lactylation, whereas combined knockout of lactate dehydrogenase A (LDHA) and lactate dehydrogenase B (LDHB) almost completely abolished this increase. The investigators also observed associations of L-lactylation with hypoxia-inducible factor 1 alpha (HIF-1α) and tumor grade in lung cancer tissues (). These findings support a model in which a glycolysis-derived lactate pool drives nuclear L-lactylation, although tissue-level associations cannot substitute for functional validation of individual sites.
Lactate crosses cell membranes mainly by bidirectional transport through monocarboxylate transporter 1 (MCT1) and monocarboxylate transporter 4 (MCT4), with net flux determined by lactate and proton gradients ().Ā A study of lung adenocarcinoma found that the E3 ubiquitin ligase synoviolin 1 (SYVN1) mediates nondegradative polyubiquitylation of MCT4 and promotes its localization to the plasma membrane. Silencing SYVN1 reduced lactate efflux and malignant phenotypes, which were partially rescued by re-expression of MCT4 (). This pathway shows that total protein abundance is an insufficient proxy for lactate flux; membrane localization and substrate gradients are equally important.
The genetic context of lung cancer can also reshape lactate export. In liver kinase B1 (LKB1)-deficient lung adenocarcinoma, MCT4-dependent lactate secretion suppresses T-cell function and weakens antitumor immunity; genetic or pharmacological targeting of MCT4 improves the immune state (). Together with the uptake of circulating lactate by human lung tumors, this mechanism supports a bidirectional lactate-shuttle model. Hypoxic or LKB1-deficient cells tend to export lactate, whereas adjacent oxidative tumor cells, immune cells, and stromal cells can take it up. The resulting regional differences determine whether lactate primarily enters the TCA cycle, alters redox balance, or is converted into a substrate for lactylation.
Lactate transport is tightly coupled to cellular redox state. As the LDH reaction interconverts lactate and pyruvate, it also redistributes reducing equivalents between reduced nicotinamide adenine dinucleotide (NADH) and its oxidized form (NAD+) (, ). Inhibiting LDH or altering monocarboxylate transporter (MCT)-mediated transport therefore affects glycolytic continuity, mitochondrial substrates, reactive oxygen species (ROS), and intracellular pH simultaneously (). If an intervention produces both reduced pan-lysine lactylation (pan-Kla) and cell death, it remains necessary to exclude the possibility that an energy crisis or redox imbalance precedes the change in lactylation (). Time-resolved measurements can address this issue. Lactate, pyruvate, NADH/NAD+, and pH should first be recorded over minutes to hours, followed by measurements of lactyl donors, site-specific lysine lactylation (Kla), and transcriptional outputs (). Lactylation can be established as a key mediator only when the site-specific change precedes the phenotype and restoration of that site rescues the phenotype.
Tracing in human lung cancer further indicates that blood-borne lactate is an important source of the local lactate pool (). Intratumoral lactylation is therefore not determined solely by glycolysis within tumor cells. Exercise, hepatic metabolism, systemic inflammation, and perioperative conditions can all alter the supply of circulating lactate. Tissue studies that infer lactylation only from LDHA or glycolytic genes will overlook systemic input and export from adjacent cells. Paired plasma and tissue tracing, arteriovenous difference measurements, and regional mapping of MCTs could further distinguish systemic lactate delivery from local lactate recycling.
The possibility that a lactate-rich inflammatory pulmonary lesion could participate in later carcinogenesis deserves separate consideration. Mycobacterium tuberculosis infection induces a Warburg-like metabolic shift in infected lung tissue, and human alveolar macrophages exposed to M. tuberculosis increase aerobic glycolysis (, ). Epidemiologic studies have also reported an increased subsequent lung-cancer risk after pulmonary tuberculosis, while pooled analyses of previous lung diseases have identified associations involving tuberculosis and pneumonia (, ). These findings establish two pieces of the proposed chain: chronic pulmonary inflammation can produce sustained glycolytic remodeling, and selected inflammatory lung diseases are associated with later lung-cancer risk. They do not, however, establish lactate or lactylation as the causal bridge. Histone lactylation can accumulate in activated macrophages and regulate late transcriptional programs (), providing a plausible mechanism through which prolonged metabolic stress could stabilize an altered inflammatory state. At present, no longitudinal human study has shown that lactate accumulation within a pneumonia nodule or tuberculous lesion induces a defined lactylation program that subsequently drives clonal transformation. Therefore, the hypothesis that lesion-associated lactylation contributes to carcinogenesis should be presented as a testable mechanistic model rather than an established causal pathway.
Exchange between a pulmonary lesion and the systemic lactate pool is also likely to be dynamic and bidirectional. In human lung cancer, isotope tracing has shown direct uptake of circulating lactate and incorporation of its carbon into the TCA cycle (); whole-body tracer studies further identify circulating lactate as a major conduit of carbohydrate carbon between tissues (), consistent with the lactate-shuttle framework (). Conversely, MCT4-dependent export from glycolytic lung-cancer cells (, ) provides a route by which lesional cells can contribute lactate to the local interstitium and, after vascular clearance, to the systemic pool. Comparable directional flux has not yet been resolved for pneumonia nodules or tuberculous granulomas. Consequently, simultaneous measurement of blood and tissue lactate concentration would be insufficient to determine origin. A direct study should combine paired plasma-lesion isotope tracing, regional MCT1/MCT4 and LDHA/LDHB mapping, spatial metabolomics, and cell-type-resolved site-specific lactylation analysis. Longitudinal sampling across inflammatory, premalignant, and malignant states wouldĀ then allow testing of whether a persistent lactate-lactylation program precedes, accompanies, or merely follows malignant transformation.
2.2 Lactylation chemistry and substrates
Lysine lactylation encompasses at least three structures: L-lactylation, D-lactylation, and Nϵ-carboxyethyllysine. L-lactylation is primarily associated with glycolysis-derived L-lactate; D-lactylation can arise through nonenzymatic transfer from D-lactoylglutathione, an intermediate of the glyoxalase system; and Nϵ-carboxyethyllysine is derived mainly from methylglyoxal-associated glycation (, ). These three modifications produce similar mass shifts and may not be fully distinguished by pan-lactylation antibodies or conventional qualitative mass spectrometry. Analytical studies indicate that L-lactylation usually predominates under intact glyoxalase conditions, whereas D-lactylation and Nϵ-carboxyethyllysine become more prominent when related metabolic pathways are disrupted (). When increased pan-Kla is detected in lung cancer tissues, the recognition range of the antibody should therefore be specified and the isomeric identity should be confirmed.
Lactylation occurs on both histone and nonhistone proteins. In site notation, K denotes lysine, the number denotes the residue position, and la denotes lactylation. Histone and nonhistone lactylation can alter transcriptional regulation and protein function through distinct mechanisms. A global lysine-lactylation analysis of normal human lung identified 724 Kla sites across 451 proteins, with substrates involved in metabolism, cytoskeletal organization, and stress responses (). However, mass spectrometric identification establishes only that a site exists. Causal interpretation additionally requires evidence that the site is regulated by lactate or a candidate enzyme and that a lysine substitution, endogenous knock-in, or site-specific antibody links the modification to a functional phenotype.
Lactyl-coenzyme A (lactyl-CoA) provides one enzymatic donor route (), although Kla abundance can be partly uncoupled from bulk lactyl-CoA levels (); thus, lactate or LDHA measurements alone cannot establish donor availability. Subcellular compartmentalization further constrains contact between donors and substrates. Subcellular proteomic mapping and compartment-resolved lactate sensors show that bulk lactate measurements can obscure local donor-substrate relationships (, ).
Lactylation also shares substrates with, or participates in crosstalk with, acetylation, phosphorylation, and ubiquitylation. Such crosstalk can alter site occupancy and protein fate, but the substrate-specific examples are discussed in the lung-cancer sections below (, ). Without matched total-proteome and other post-translational-modification controls, global lactylome studies cannot readily distinguish true changes in site occupancy from changes in protein abundance. Site-specific studies in lung cancer should report the modified peptide, its unmodified counterpart, and total protein abundance, and should assess competing acyl modifications at the same lysine whenever possible.
2.3 Lactylation writers and erasers
Several acyltransferases, including histone acetyltransferase p300 and CREB-binding protein (p300/CBP), lysine acetyltransferase 2A (KAT2A), histone acetyltransferase binding to origin recognition complex subunit 1 (HBO1), lysine acetyltransferase 8 (KAT8), and Tat-interactive protein 60 kDa (TIP60), have been linked to lactylation, with HBO1 supported by catalytic, proteomic, and chromatin-level evidence (). Because these enzymes can generally catalyze acetylation or other forms of acylation as well, phenotypic changes following inhibition of a writer should be complemented by site-specific mutants and metabolic rescue to establish the independent contribution of lactylation.
Alanyl-tRNA synthetases 1 and 2 (AARS1 and AARS2) provide an additional lactate-sensing route and have been shown to lactylate substrates including cyclic GMP-AMP synthase (cGAS) and tumor suppressor p53 (, ). The former evidence derives mainly from infection and innate-immunity models, whereas the latter comes from models of multiple cancers. These findings provide candidate mechanisms for lung cancer, although the relevant substrates still require validation across tumor protein p53 gene (TP53) states and histological subtypes.
Lactylation is reversible: histone deacetylases 1ā3 (HDAC1-3) and selected sirtuins can remove lactyl groups from histone and nonhistone substrates (, ). Their net activity can be metabolically context dependent, which limits simple classification of these enzymes as constitutive delactylases24.
Substrate selection by writers and erasers is further controlled by chromatin-targeting factors and protein complexes. HBO1-dependent histone H3 lysine 9 lactylation (H3K9la) is concentrated at transcription start sites (), whereas SATB homeobox 2 (SATB2) can recruit histone deacetylase 3 (HDAC3) to the lipocalin 2 (LCN2) regulatory region and induce local delactylation (). This lung-cancer example illustrates why local enzyme recruitment can be more informative than global writer or eraser abundance; this locus-specific pathway is summarized in TableĀ 1 ().
TableĀ 1
| Histone Kla pathway | Regulatory mechanism | Biological consequence | Lung-cancer context/evidence | Ref. |
|---|---|---|---|---|
| H3K18la/POM121-MYC-PD-L1 | H3K18la at the POM121 regulatory region increases POM121 transcription, MYC nuclear transport, and CD274 transcription. | PD-L1 accumulation and suppression of CD8+ T-cell cytotoxicity. | NSCLC tissues, cells, and mouse models; ChIP and functional rescue support a direct axis. | () |
| H3K18la/YTHDF2-SFRP2-Wnt | Promoter H3K18la increases YTHDF2, which accelerates decay of m6A-modified SFRP2 and releases Wnt signaling. | Stemness, proliferation, and glycolytic positive feedback. | NSCLC cellular and xenograft models; LDHA-dependent regulation. | () |
| H3K18la/KRT19-p21 | H3K18la activates KRT19; KRT19 suppresses p53-CDKN1A signaling and promotes p21 ubiquitylation. | Senescence escape and sustained proliferation. | NSCLC tissues, cells, and mouse models. | () |
| H4K5la/EZH2-EED-PRC2-MHC-I | p300-associated H4K5la activates EZH2 and EED, increasing PRC2 activity and repressing MHC-I expression. | Reduced antigen presentation and immune escape. | SCLC-A cells and mouse models; lactate rescue after LDH/LDHA perturbation. | () |
| H4K8la/H4K16la/Sp1-TERT | Restoration of LKB1 alters H4K8la/H4K16la and is associated with reduced Sp1 activity and TERT expression. | Telomere damage and cellular senescence. | LKB1-deficient A549-based models; illustrates genotype-dependent site behavior. | () |
| H3K9la/SATB2-HDAC3-LCN2 | SATB2 recruits HDAC3 to the LCN2 regulatory region and promotes local H3K9 delactylation. | Reduced LCN2 transcription, tumor growth, and metastasis. | Lung-cancer cells and mouse models; demonstrates locus-specific reversibility. | () |
Integrated summary of histone lactylation pathways in lung cancer.
H3K18la, histone H3 lysine 18 lactylation; H4K5la, histone H4 lysine 5 lactylation; H4K8la/H4K16la, histone H4 lysine 8/16 lactylation; H3K9la, histone H3 lysine 9 lactylation; POM121, POM121 transmembrane nucleoporin; MYC, MYC transcription factor; PD-L1, programmed death ligand 1; CD274, the gene encoding PD-L1; NSCLC, non-small cell lung cancer; ChIP, chromatin immunoprecipitation; YTHDF2, YTH N6-methyladenosine RNA binding protein 2; SFRP2, secreted frizzled-related protein 2; m6A, N6-methyladenosine; LDHA, lactate dehydrogenase A; KRT19, keratin 19; p21, cyclin-dependent kinase inhibitor p21; p53, tumor suppressor p53; CDKN1A, cyclin dependent kinase inhibitor 1A, the gene encoding p21; EZH2, enhancer of zeste 2; EED, embryonic ectoderm development; PRC2, polycomb repressive complex 2; MHC-I, major histocompatibility complex class I; SCLC-A, small cell lung cancer subtype A; LDH, lactate dehydrogenase; LKB1, liver kinase B1; Sp1, specificity protein 1; TERT, telomerase reverse transcriptase; SATB2, SATB homeobox 2; HDAC3, histone deacetylase 3; LCN2, lipocalin 2.
Because several lactylation writers and erasers also regulate other acyl modifications, inhibitor- or knockdown-induced phenotypes cannot automatically be assigned specifically to lactylation. Site-specific perturbation and rescue therefore remain necessary when a lactylation-dependent mechanism is proposed.
2.4 Evidence for mechanistic inference
Three categories of concepts are frequently conflated in lactate-related studies. Accordingly, this review treats lactate metabolism, proton-coupled acidification, and covalent lactylation as distinct levels of evidence; perturbation of LDH or MCTs alone cannot assign a phenotype specifically to lactylation.
A credible mechanistic chain for lactylation in lung cancer should include at least four levels. In concise form, this requires identification of the lactate source and donor, validation of the modified site, site- or enzyme-level perturbation with rescue, and confirmation of the phenotype in the relevant lung-cancer cell and spatial context.
Site-directed mutations also require cautious interpretation. Because lysine substitutions can alter properties beyond lactylation, site mutants should be interpreted together with wild-type rescue and orthogonal site-level evidence.
Spatial evidence additionally requires validation of the cellular source. Spatial transcriptomic or pan-Kla signals can identify candidate regions, but directional lactate transfer and a functional lactylation site require orthogonal validation. The metabolic and validation framework is summarized in FigureĀ 1.
FigureĀ 1
3 Cell-intrinsic lactylation in lung cancer
Lung cancer cells both produce lactate and take it up for oxidation. Lactylation consequently provides an interface through which metabolic state is sensed and transcription, protein stability, and organelle function are remodeled. Current direct evidence centers on four groups of phenotypes: maintenance of proliferation and stemness, attenuation of immune recognition, reinforcement of metabolic adaptation, and enhancement of DNA repair and treatment resistance. Different pathways complement one another across distinct timescales. Nonhistone lactylation can rapidly change protein activity or half-life, whereas histone lactylation establishes more persistent transcriptional programs; together, these processes ultimately form positive feedback loops.
3.1 Metabolic inputs
Human lung tumors contain both lactate-exporting and lactate-utilizing cells. Hypoxia, hypoxia-inducible factor (HIF) signaling, and high glycolytic activity drive LDHA- and MCT4-associated export; well-perfused cells with higher MCT1 expression and intact mitochondria can take up and oxidize lactate. When lactate was added to non-small cell lung cancer (NSCLC) cells, glucose uptake and glycolysis declined, mitochondrial membrane potential was maintained, and promoter lactylation changed at metabolic genes including hexokinase 1 (HK1), pyruvate kinase M1/2 (PKM), succinate dehydrogenase complex flavoprotein subunit A (SDHA), and isocitrate dehydrogenase (NAD+) 3 non-catalytic subunit gamma (IDH3G) (). This creates metabolic feedback in which lactate accumulation alters the transcription of metabolic genes and subsequently redistributes glycolytic and oxidative metabolism. The study was based primarily on cellular models and did not resolve every histone site. It therefore supports metabolic plasticity but is insufficient to generalize across all lung cancer subtypes.
Genetic background can alter the relationship between lactate concentration and modification at a specific site. Restoration of LKB1 in LKB1-deficient A549 cells increased lactate production but decreased histone H4 lysine 8 lactylation (H4K8la) and histone H4 lysine 16 lactylation (H4K16la), followed by reduced specificity protein 1 (Sp1) activity, telomerase reverse transcriptase (TERT) suppression, telomere damage, and cellular senescence (). These findings indicate that total lactate and modification at an individual site do not have a fixed positive relationship. Serine/threonine kinase 11 (STK11), which encodes LKB1, may also alter the modification landscape through chromatin recruitment, donor allocation, or delactylation. Comparisons of lactylation among patients should therefore record histological type, driver alterations, oxidative capacity, and sampling region concurrently.
3.2 Histone lactylation and transcriptional states
Rather than treating each histone-lactylation cascade as an isolated pathway, the available lung-cancer evidence can be organized into three recurrent functional modules: immune evasion, maintenance of proliferative or stem-like states, and context-dependent chromatin adaptation. Histone H3 lysine 18 lactylation (H3K18la) is the most recurrent histone mark, but its functional output depends on the occupied regulatory locus: one pathway increases programmed death ligand 1 (PD-L1) expression through POM121 transmembrane nucleoporin (POM121) and the MYC transcription factor; another reinforces stemness and glycolytic feedback through YTH N6-methyladenosine RNA binding protein 2 (YTHDF2)-dependent regulation of secreted frizzled-related protein 2 (SFRP2)/Wnt signaling; and keratin 19 (KRT19)-cyclin-dependent kinase inhibitor p21 signaling facilitates escape from senescence (, , ). In small cell lung cancer subtype A (SCLC-A), histone H4 lysine 5 lactylation (H4K5la) increases expression of enhancer of zeste 2 (EZH2) and embryonic ectoderm development (EED), two components of polycomb repressive complex 2 (PRC2), thereby enhancing PRC2-mediated suppression of major histocompatibility complex class I (MHC-I) and reducing antigen presentation (). Additional lung-cancer studies show that LKB1-dependent changes in H4K8la/H4K16la can influence Sp1-TERT signaling, whereas SATB2-directed HDAC3 recruitment removes H3K9la at the LCN2 regulatory region (, ). Together, these findings indicate that histone lactylation converges on a limited set of biological outputs while remaining highly dependent on histological subtype, driver context, chromatin locus, and local writer/eraser recruitment. The principal pathways and their evidence levels are summarized in TableĀ 1. Importantly, these mechanisms were established in different lung-cancer models and should not be assumed to coexist in the same tumor without direct validation.
3.3 Nonhistone lactylation
3.3.1 Signaling, transcription, and ribonucleic acid regulation
Nonhistone lactylation of signaling and regulatory proteins in lung cancer frequently acts through protein-fate control. Lactylation prolongs the half-life or limits ubiquitin-dependent degradation of insulin-like growth factor 1 receptor (IGF1R), RNA binding motif protein 15 (RBM15), and programmed death ligand 1 (PD-L1), thereby increasing the effective abundance of these proteins, whereas lactylation of cyclic GMP-AMP synthase (cGAS) has the opposite effect and promotes proteasomal clearance (, ā). This bidirectional control is important because nonhistone lactylation should not be interpreted simply as a stabilizing modification; its effect on abundance depends on the modified lysine, the relevant ubiquitin machinery, and the substrate.
The same functional class also includes transcriptional and RNA-regulatory outputs. SRY-box transcription factor 9 (SOX9) lactylation links hypoxia and glycolytic lactate production to enhanced stemness, migration, and invasion, while RBM15 K850la maintains its interaction with the methyltransferase 3 (METTL3) complex and increases N6-methyladenosine (m6A)-related RNA regulation (, ). Together with IGF1R, PD-L1, and cGAS, these examples show that nonhistone lactylation can regulate receptor signaling, transcription-factor output, RNA modification, immune-checkpoint stability, and innate immune sensing without requiring a common downstream pathway.
3.3.2 Metabolic and mitochondrial proteins
A second group comprises proteins that directly determine nutrient handling and metabolic output. Apolipoprotein C-II (APOC2) K70la increases APOC2 stability and promotes lipoprotein lipase (LPL)-dependent extracellular lipolysis; hexokinase 2 (HK2) K873la limits ubiquitination, increases HK2 stability and glycolytic capacity; and enolase 1 (ENO1) lactylation increases glycolytic output and lactate production (ā). These mechanisms explicitly connect nonhistone lactylation to both protein abundance and metabolic enzyme function: for HK2, the dominant evidence involves stabilization together with increased glycolytic capacity, whereas ENO1 lactylation is associated with higher pathway flux and additional lactate production.
Mitochondrial regulation extends this principle beyond glycolysis. Death-associated protein kinase 2 (DAPK2)-dependent changes in lactylation of mitochondrial cristae-organizing protein Mic60 remodel cristae organization and increase oxidative phosphorylation, supporting anoikis resistance, metastasis, and epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) resistance (). Thus, the metabolic consequences of nonhistone lactylation include altered substrate availability, enzyme stability, glycolytic output, and mitochondrial oxidative capacity. These changes can generate positive feedback because enhanced glycolysis increases the lactate pool that supports further lactylation.
3.3.3 Genome repair proteins
DNA-repair proteins form a third functional class. Histone acetyltransferase 1 (HAT1)-mediated replication protein A1 (RPA1) K73 lactylation enhances recruitment of RPA1 to DNA lesions and homologous-recombination repair, thereby increasing radioresistance in lung adenocarcinoma; lactylome profiling has also implicated the DNA end-binding proteins Ku70 and Ku80 in nonhomologous end joining (NHEJ) (, ). In this class, the principal effect is altered protein recruitment and repair activity rather than a demonstrated change in steady-state protein abundance. Nibrin (NBS1) K388la provides cross-cancer support for the same principle, although its direct applicability to lung cancer remains to be established (). The major nonhistone substrates, their functional categories, and their effects on protein abundance or metabolic activity are summarized in TableĀ 2.
TableĀ 2
| Functional class | Target/site | Principal mechanism | Effect on abundance/metabolic activity | Functional outcome/evidence boundary | Ref. |
|---|---|---|---|---|---|
| Signaling receptor | IGF1R Kla (site not defined) | Lactylation extends IGF1R half-life and strengthens IGF1 binding. | Increased receptor stability/abundance; increased glycolysis is a downstream output. | Proliferation and migration; modified site and writer remain undefined. | () |
| RNA-regulatory protein | RBM15 K850la | Suppresses ubiquitin-mediated degradation and maintains interaction with METTL3/WTAP. | Increased RBM15 stability/abundance; increased m6A regulatory output. | NSCLC proliferation and migration; K850R functional rescue. | () |
| Immune checkpoint | PD-L1 K280la | AARS1-mediated lactylation reduces HUWE1 recognition and ubiquitination. | Increased PD-L1 stability and steady-state abundance. | Immune escape; site-specific K280R evidence. | () |
| Innate immune sensor | cGAS K21/K415la | Promotes nuclear export and proteasomal degradation of cGAS. | Decreased cGAS abundance. | Reduced interferon signaling and innate immune sensing. | () |
| Transcription factor | SOX9 Kla | Hypoxia/glycolysis-dependent lactylation enhances SOX9 transcriptional output. | Functional activity is enhanced; effect on abundance and exact site remain unresolved. | Stemness, migration, and invasion in NSCLC. | () |
| Lipid-metabolism protein | APOC2 K70la | Stabilizes APOC2 and enhances LPL-dependent extracellular lipolysis. | Increased APOC2 stability; increased extracellular lipolytic output. | Fatty-acid supply, Treg enrichment, and ICI resistance. | () |
| Metabolic enzyme | HK2 K873la | Limits HK2 ubiquitination and degradation. | Increased HK2 stability/abundance and glycolytic capacity. | Invasion and cisplatin resistance; K873R evidence. | () |
| Metabolic enzyme | ENO1 Kla | Lactate-induced ENO1 lactylation forms a positive feedback loop. | Increased glycolytic output and lactate production. | Osimertinib resistance; site-specific mechanism remains less resolved. | () |
| Mitochondrial protein | Mic60 Kla | DAPK2 loss alters Mic60 lactylation and cristae organization. | Enhanced OXPHOS/mitochondrial function; abundance effect not established. | Anoikis resistance, metastasis, and EGFR-TKI resistance. | () |
| DNA-repair protein | RPA1 K73la | HAT1-mediated lactylation enhances ssDNA/MRN binding and lesion recruitment. | Increased repair recruitment and HR activity rather than demonstrated abundance change. | Radioresistance in LUAD; K73R evidence. | () |
| DNA-repair proteins | Ku70/Ku80 Kla | Lactylome profiling links Kla to the NHEJ machinery. | Reducing lactylation lowers NHEJ efficiency; individual-site effects remain unresolved. | Candidate mechanism from lung-adenocarcinoma multiomics. | () |
Functional classification and mechanistic consequences of nonhistone lactylation in lung cancer.
Kla, lysine lactylation; IGF1R, insulin-like growth factor 1 receptor; IGF1, insulin-like growth factor 1; RBM15, RNA binding motif protein 15; METTL3, methyltransferase 3; WTAP, WT1 associated protein; m6A, N6-methyladenosine; NSCLC, non-small cell lung cancer; PD-L1, programmed death ligand 1; AARS1, alanyl-tRNA synthetase 1; HUWE1, HECT, UBA and WWE domain containing E3 ubiquitin protein ligase 1; cGAS, cyclic GMP-AMP synthase; SOX9, SRY-box transcription factor 9; APOC2, apolipoprotein C-II; LPL, lipoprotein lipase; Treg, regulatory T cell; ICI, immune checkpoint inhibitor; HK2, hexokinase 2; ENO1, enolase 1; Mic60, mitochondrial cristae-organizing protein Mic60; DAPK2, death-associated protein kinase 2; OXPHOS, oxidative phosphorylation; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; RPA1, replication protein A1; HAT1, histone acetyltransferase 1; ssDNA, single-stranded DNA; MRN, MRE11-RAD50-nibrin complex; HR, homologous recombination; LUAD, lung adenocarcinoma; Ku70/Ku80, DNA end-binding proteins; NHEJ, nonhomologous end joining. In modification-site notation, K denotes lysine, the number denotes the residue position, and la denotes lactylation; K-to-R notation denotes lysine-to-arginine substitution.
3.4 Intracellular feedback and reversibility
The pathways described above can be organized into three tiers of feedback. The first tier expands lactate input through increased glycolysis associated with insulin-like growth factor 1 receptor (IGF1R) signaling, YTHDF2-mediated decay of SFRP2 messenger RNA (mRNA) with Wnt activation, hexokinase 2 (HK2), and enolase 1 (ENO1). The second tier maintains malignant states through KRT19-p21-mediated escape from senescence, SOX9-associated stemness, Mic60-associated mitochondrial adaptation, and RPA1-associated DNA repair. The third tier reduces immune recognition through H4K5la-driven PRC2 repression of major histocompatibility complex class I, H3K18la/POM121-MYC-dependent upregulation of programmed death ligand 1, and direct PD-L1 K280 lactylation. These three tiers can occur sequentially within the same cell or be distributed among distinct subpopulations.
The lactylation network nevertheless remains reversible. A lung cancer study found that SATB2 recruits HDAC3 to the LCN2 regulatory region, promotes H3K9 delactylation, and represses LCN2 transcription, thereby inhibiting tumor growth and metastasis (). This finding links a chromatin-targeting factor, an eraser, and a defined target gene and indicates that delactylation can be directed by a DNA-binding protein to a specific region rather than acting as indiscriminate global removal. The lactylation phenotype of lung cancer cells is therefore determined by the balance between local installation and local removal. Its output depends on substrate and chromatin location and cannot be fully represented by global pan-Kla intensity (FigureĀ 2).
FigureĀ 2
4 Immune and stromal reprogramming
This section focuses on cell-type-specific evidence for how tumor-derived lactate and lactylation reshape immune and stromal states in lung cancer. Interpretation centers on the recipient cell, the metabolic fate of imported lactate, and the molecular changes that stabilize the resulting phenotype.
4.1 T-cell function and exhaustion
Lactate has context-dependent and bidirectional effects on cluster of differentiation 8-positive (CD8+) T cells. During prolonged exposure to a tumor environment with high lactate, monocarboxylate transporter 11 (MCT11)-mediated uptake alters the intracellular redox state and reinforces the exhaustion program. Deletion of MCT11 improves the metabolism and effector function of exhausted T cells and enhances tumor control (). In small cell lung cancer (SCLC), tumor-derived lactate induces H3K18la in naive CD8+ TĀ cells, activates the orphan nuclear receptor Nur77, and produces persistent but ineffective T-cell-receptor signaling, ultimately weakening antigen-specific cytotoxicity (). Together, these pathways show that chronic exogenous lactate input can stabilize a hyporesponsive state at both metabolic and chromatin levels.
Conversely, lactate generated by T-cell activation itself can produce moderate H3K18la and support effector-gene transcription and cellular function. Perturbation of endogenous lactate production or histone lactylation impairs metabolic adaptation and antitumor activity in CD8+ T cells (). The direction of the lactate response therefore depends on its source, concentration, duration of exposure, and cellular state. Endogenous lactylation generated during acute activation can participate in normal effector differentiation, whereas persistently high tumor-derived lactate together with acidification is more likely to induce exhaustion.
4.2 Regulatory T cells
Regulatory T (Treg) cells can use tumor-derived lactate to maintain their function. MCT1-dependent lactate uptake supports the metabolism and suppressive phenotype of intratumoral Treg cells, whereas Treg-specific deletion of MCT1 impairs their adaptation within tumors (). Lactate in highly glycolytic tumors can also promote programmed cell death protein 1 (PD-1) expression in Treg cells and alter both their suppressive function and their population dynamics after PD-1 blockade (). These findings chiefly establish metabolic and signaling effects of lactate and do not, by themselves, demonstrate covalent lactylation.
Cross-cancer studies have shown that lactate can induce lactylation of the membraneācytoskeleton linker moesin (MOESIN) at K72, strengthen interactions between MOESIN and the transforming growth factor beta (TGF-β) receptor (TGFBR) machinery, and enhance downstream SMAD family member 3 (SMAD3) signaling, thereby promoting Treg-cell generation and suppressive function (). This site provides a causal example of direct Treg regulation by lactylation, although the principal evidence does not derive from lung cancer. When considered together with MCT4-dependent lactate export and Treg enrichment in lung cancer, a plausible model is that tumor-derived lactate serves as a carbon source for Treg cells and, under specific conditions, amplifies TGF-β signaling through MOESIN lactylation. The latter link requires site-specific validation in lung cancer tissues.
4.3 Tumor-associated macrophages and myeloid suppression
Direct evidence in lung adenocarcinoma links tumor-derived lactate to histone lactylation in macrophages. N-myc downstream regulated 1 (NDRG1) inhibits LDHA ubiquitylation, increases LDHA stability, and enhances lactate production by tumor cells. After the released lactate enters macrophages, H3K18la increases; cleavage under targets and tagmentation (CUT&Tag) showed enrichment of this modification at regulatory regions of the macrophage scavenger-receptor gene CD163 and multiple immunosuppressive genes, driving macrophages toward an immunosuppressive phenotype (). This intercellular chain encompasses protein stability in tumor cells, lactate export, chromatin modification in recipient cells, and the immune phenotype and therefore provides important direct evidence for a lactylation niche in lung cancer.
Studies in other tumor types further show that myeloid-cell lactylation can couple to RNA modification. In tumor-infiltrating myeloid cells, H3K18la promotes METTL3 transcription, enhances m6A writing, and maintains immunosuppressive programs (). This mechanism conceptually parallels the YTHDF2 and RBM15 pathways in lung cancer cells. Lactylation can repeatedly engage the m6A machinery in different cell types, whereas the target transcripts and functional outputs are determined by cellular identity. The applicability of the myeloid METTL3 pathway to lung cancer still requires cell-type-resolved detection of the relevant sites.
Metabolite exchange can also occur between tumor cells and macrophages. Dynamic single-cell metabolomics has recorded lactate-related carbon flow and changes in metabolic state after coculture of the two cell types, providing a direct route for measuring intercellular lactate flux (). This supports intercellular lactate exchange but does not establish a site-resolved transfer mechanism in lung cancer.
4.4 Natural killer cells, dendritic cells, and neutrophils
The effects of lactylation on innate immune cells have received mechanistic support across several tumor types. Sustained exposure of natural killer (NK) cells to tumor-derived lactate induces extensive lactylation and reduces cytotoxicity, whereas lowering lactylation restores their killing capacity (). In dendritic cells, lactate can activate a sterol regulatory element-binding protein 2 (SREBP2)-associated tolerogenic maturation program and impair antigen presentation and T-cell priming (); another study linked mitochondrial pyruvate carrier-dependent lactate production to H3K18la and immunosuppressive transcription (62). These findings indicate that dendritic cells are influenced by extracellular lactate and can also generate lactylation inputs through their own metabolism.
Histone lactylation in neutrophils within hypoxic brain tumors can drive immunosuppressive reprogramming (). This finding has cellular and mechanistic value, although the site-specific landscape and spatial location of neutrophils in lung cancer have not been validated to the same extent. Evidence concerning NK cells, dendritic cells, and neutrophils should therefore be considered a cross-cancer support tier. It provides testable candidate chains for lung cancer but cannot replace causal data from lung cancer tissues.
4.5 Cancer-associated fibroblasts and endothelial cells
Cancer-associated fibroblasts (CAFs) can serve as both recipients and sources of lactate. In epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI)-resistant lung cancer, collagen triple helix repeat containing 1-positive (CTHRC1+) CAFs increase hexokinase 2 (HK2) expression, glycolysis, and lactate production in tumor cells; the resulting increase in lactate promotes H3K18la within CAFs and maintains the CTHRC1-associated state, forming an intercellular positive feedback loop (). This circuit links stromal state to tumor metabolic adaptation and can explain why lactate continues to accumulate and resistant cells persist at invasive fronts or in fibrotic regions.
Malignant pleural effusion (MPE) provides another spatial environment in lung cancer. H3K18la within cancer-associated fibroblasts can activate forkhead box O3 (FOXO3)-dependent C-X-C motif chemokine ligand 16 (CXCL16) signaling and is linked to enrichment of tumor necrosis factor receptor 2-positive (TNFR2+) regulatory T cells and pleural-effusion progression (). Pleural effusions differ markedly from the primary tumor parenchyma in oxygen supply, fluid exchange, and cellular composition. This mechanism is therefore better suited to defining a metastatic serosal-cavity niche and cannot be generalized directly to all primary tumors.
Endothelial cells can take up lactate through MCT1 and activate the nuclear factor kappa B (NF-ĪŗB)/interleukin 8 (IL-8) pathway, thereby promoting angiogenesis (66). This classic study established an endothelial signaling effect of lactate without requiring covalent lactylation. Accordingly, current evidence supports a lactate-signaling mechanism in endothelium rather than a validated endothelial lactylation pathway.
4.6 Intercellular feedback
Collectively, the available evidence indicates at least three sets of coupled feedback loops in the lung cancer microenvironment. The first links tumor cells and macrophages. NDRG1 stabilizes LDHA and increases lactate export, after which macrophage H3K18la increases the expression of CD163 and immunosuppressive genes and reduces local immune clearance. Other tumor models have likewise shown that tumor-derived lactate can induce protumor macrophage polarization and that glucose-driven histone lactylation can maintain the immunosuppressive program of monocyte-derived macrophages (, ). The second links tumor cells and CAFs. CTHRC1+ CAFs enhance tumor glycolysis, whereas tumor-derived lactate maintains CAF H3K18la and a resistance-promoting state. Another NSCLC study found that CAFs enhance glycolysis and DNA-damage repair in tumor cells, providing independent evidence for stroma-driven metabolic resistance (69). The third links tumor cells and lymphocytes. Forkhead box P3 (Foxp3)-mediated metabolic reprogramming enables Treg cells to adapt to a low-glucose, high-lactate environment; in acute myeloid leukemia, lactate can also increase thymocyte selection-associated high mobility group box (TOX) and PD-1 expression in CD8+ T cells and promote exhaustion (70, 71). It can therefore be inferred that highly glycolytic tumor subpopulations are more likely to continue expanding once immune selection pressure has weakened.
These feedback loops show that a lactylation niche is not established by a single cell type. Tumor cells supply lactate, MCTs help determine transmembrane lactate flux and its regional direction, and writers, erasers, and the pre-existing chromatin state of recipient cells collectively shape the modification output. Cytokines and metabolic substrates then return signals to tumor cells. Tumor vascular topology can generate distance-dependent metabolic gradients and immune-cell distributions (72). The next question therefore concerns tissue architecture: which cells are adjacent in each location, whether lactate gradients span those distances, and why different regions develop opposing immune states.
Intercellular feedback also contains response layers with different durations. Lactate-proton transport first determines the regional availability of lactate and local acid-base conditions; nonhistone lactylation can regulate protein stability and subcellular trafficking; and histone lactylation can establish persistent immunosuppressive transcriptional programs. Current studies have not shown that these layers follow a fixed sequence in every cell type. They are better understood as responses with different kinetics and durations that can occur in parallel. As immunosuppressive macrophage programs, resistance-promoting CAF states, and T-cell exhaustion become established, cytokines, extracellular matrix, and immune selection pressure can further prolong the lifetime of the niche. Lung fibroblasts primed on a stiff matrix retain myofibroblast activity for at least two weeks after transfer to a soft matrix; hypoxic regions can also attract and retain tumor-associated macrophages and cytotoxic T cells and reprogram them toward immunosuppressive phenotypes (73, 74). These findings support the inference that established CAF architecture and myeloid neighborhoods may continue to maintain suppression even after a transient local decrease in lactate. Observations at a single time point can readily conflate initiating factors with maintenance factors.
The baseline state of the recipient cell determines the strength of feedback. Cell-autonomous lactylation during early CD8+ T-cell activation can support effector function (), whereas prolonged exposure to exogenous lactate can reinforce exhaustion through MCT11 and Nur77 (, ); Treg cells and some myeloid cells can use lactate to maintain adaptation (). Lactate concentration alone is therefore insufficient to predict an immune outcome. Incorporating the differentiation stage of the recipient cell, T-cell-receptor stimulation, MCT profile, mitochondrial capacity, and writer and eraser states into the model is necessary to explain why similar lactate exposures generate different phenotypes (FigureĀ 3).
FigureĀ 3
5 Spatial immunometabolic niches
A spatial immunometabolic niche can be defined as a tissue unit maintained jointly by local oxygen supply, nutrients, lactate and proton gradients, cellular composition, and intercellular distance. The candidate niches and their evidence boundaries are summarized in TableĀ 3. Lung-cancer studies map regional metabolites and cellular neighborhoods more convincingly than they map lactylation at defined sites (75ā77).
TableĀ 3
| Niche | Metabolic architecture | Candidate output | Evidence boundary | Ref. |
|---|---|---|---|---|
| Hypoxic glycolytic core | Low O2, high LDHA and MCT4, and restricted clearance create a major lactate/H+ source. | Nuclear Kla, CD8+ T-cell and NK-cell dysfunction, and relative Treg/myeloid adaptation. | Human lung tumor metabolism and spatial metabolomics support regional heterogeneity; cell-specific spatial Kla remains unmeasured. | (, , , , , , 76) |
| Invasive front and CAF boundary | CTHRC1+ or POSTN+ CAFs enhance tumor glycolysis; tumor-derived lactate feeds back to CAF H3K18la. | TGF-β/TGFBR/SMAD3/HK2 signaling, CAF-state maintenance, invasion, and EGFR-TKI resistance. | The CTHRC1 feedback loop is validated in lung cancer, while its precise spatial range requires direct metabolite mapping. | (, , 82, 83) |
| Perivascular oxidative region | MCT1-high tumor and endothelial cells import lactate; LDHB supports pyruvate formation and TCA-cycle entry. | Oxidative symbiosis and endothelial ROS/NF-ĪŗB/IL-8 signaling with angiogenesis. | Human tracing validates lactate oxidation, but spatial coupling between flux and defined Kla sites remains unresolved. | (, 66, 84) |
| Immune-active and TLS-rich region | CXCL13-associated immune neighborhoods, TLSs, HEVs, DCs, and TCF1+ stem-like CD8+ T cells form dense immune contacts. | Efficient antigen presentation and cytotoxic responses may create a local boundary to lactate-mediated suppression. | Spatial immune architecture is associated with outcome; local lactate gradients and site-specific Kla have not been directly mapped. | (87, 89ā91) |
| Metastatic and serosal niches | MPE, lymph nodes, and brain metastases provide distinct oxygen, lipid, immune, and lactate-shuttle environments. | CAF H3K18la activates FOXO3 and CXCL16 signaling and promotes TNFR2+ Treg recruitment in MPE; other sites may select different Kla programs. | The MPE pathway has direct support, while paired spatial tracing and site-resolved Kla data remain limited for lymph-node and brain metastases. | (, 92, 93, 95) |
Spatial immunometabolic niches in lung cancer and current evidence boundaries.
LDHA/LDHB, lactate dehydrogenase A/B; MCT1/MCT4, monocarboxylate transporter 1/4; Kla, lysine lactylation; NK, natural killer; Treg, regulatory T cell; CAF, cancer-associated fibroblast; CTHRC1, collagen triple helix repeat containing 1; POSTN, periostin; H3K18la, histone H3 lysine 18 lactylation; TGF-β, transforming growth factor beta; TGFBR, transforming growth factor beta receptor; SMAD3, SMAD family member 3; HK2, hexokinase 2; EGFR-TKI, epidermal growth factor receptor tyrosine kinase inhibitor; TCA, tricarboxylic acid; ROS, reactive oxygen species; NF-κB, nuclear factor kappa B; IL-8, interleukin 8; TLS, tertiary lymphoid structure; CXCL13, C-X-C motif chemokine ligand 13; HEV, high endothelial venule; DC, dendritic cell; TCF1, T cell factor 1; MPE, malignant pleural effusion; FOXO3, forkhead box O3; CXCL16, C-X-C motif chemokine ligand 16; TNFR2, tumor necrosis factor receptor 2. A superscript plus sign indicates marker-positive cells.
A niche also has directionality and boundaries. Lactate diffuses from source cells toward recipient cells and is transported by MCTs, vascular and interstitial flow determines the direction of clearance, and extracellular-matrix density limits diffusion distance (78, 79). Accordingly, a high-lactate region is treated here as a candidate lactylation niche unless source, recipient, and downstream site-specific phenotype are spatially connected (80, 81).
5.1 Hypoxic glycolytic core
Tumor cores located far from functional blood vessels commonly experience hypoxia, nutrient deprivation, and restricted clearance of metabolic waste. HIF-associated glycolysis, LDH activity, and MCT4 membrane localization collectively expand lactate export. Accumulation of lactate and protons impairs the effector functions of CD8+ T cells and NK cells while conferring an adaptive advantage on Treg cells and some myeloid cells. Hypoxia-induced nuclear L-lactylation may also convert transient fluctuations in oxygen supply into a more persistent transcriptional state ().
Spatial metabolomics of lung squamous cell carcinoma has identified tumor-specific and stroma-specific metabolic subtypes, with the stromal metabolic state associated with response to neoadjuvant therapy (76). This finding indicates that adjacent stroma outside the core also participates in metabolic selection. These data define regional metabolic states but do not directly establish cell-specific lactylation.
5.2 Invasive front and fibroblast boundary
The invasive front is enriched in CAFs, extracellular matrix undergoing remodeling, migratory tumor cells, and myeloid cells. In spatial-transcriptomic studies of NSCLC, periostin-positive (POSTN+) CAFs are associated with immunosuppression and adverse clinical features (82). The positive feedback loop linking CTHRC1+ CAFs and tumor cells through CTHRC1, glycolysis, lactate, and H3K18la provides a direct molecular explanation for this boundary (). CAFs increase tumor-cell HK2 and lactate production, while lactate in turn stabilizes the CAF state and establishes a local environment favorable to EGFR-TKI-resistant cells.
Colocalization of cluster of differentiation 14-positive and apolipoprotein E-positive (CD14+APOE+) myeloid cells and matrix metalloproteinase 7-positive (MMP7+) tumor cells is associated with a poorer response to immunotherapy in NSCLC (83). Lactylation has not been measured directly in this neighborhood, although its cellular composition can be linked conceptually to the NDRG1-LDHA-macrophage H3K18la pathway (). The most conservative model treats spatial colocalization as a candidate context and then tests whether tumor-cell LDHA, local lactate, macrophage H3K18la, and CD163 vary continuously with intercellular distance.
5.3 Perivascular oxidative regions
Oxygen and nutrients are relatively abundant in perivascular regions, where tumor cells with high MCT1 expression can take up lactate from hypoxic regions and direct it into the TCA cycle (). This metabolic symbiosis reduces lactate accumulation near the producing cells while supplying oxidative cells with carbon. Endothelial cells can also take up lactate and activate proangiogenic signaling (66), further altering perfusion and lactate clearance.
Spatial multiplex immunofluorescence studies have shown that the metabolic phenotypes of tumor and immune cells in NSCLC vary with spatial distance and neighborhood composition (84). These maps provide spatial context but do not directly measure lactate flux.
Perivascular regions may also act as sinks within lactate gradients. Sustained lactate uptake by oxidative tumor cells and endothelial cells can lower the concentration in their immediate vicinity and maintain a concentration difference relative to more distant hypoxic regions (85). If MCT1-expressing cells consume large amounts of lactate, their lactylation signal may increase after uptake or remain low because of rapid oxidation. The outcome depends on the rate of lactyl-donor formation relative to mitochondrial clearance. This competition between oxidation and modification remains to be resolved directly in spatially defined lung-cancer regions (86).
5.4 Immune-active regions and tertiary lymphoid structures
Spatially organized neighborhoods of myeloid and T cells exist in lung cancer tissues, and different neighborhoods are associated with immune evasion and clinical outcomes (87). Single-cell and spatial transcriptomics have further revealed differences in communication involving immune checkpoints, epidermal growth factor receptor (EGFR) ligands, and angiogenesis across lung cancer subtypes (88). In some lung cancers, stem-like tumor cells, antigen-presenting cells, and lymphocytes form spatially ordered stemness-immune hubs whose architecture is associated with response to immunotherapy (89). The high immune-cell density and frequent intercellular contacts in these regions may create a spatial boundary to lactate-mediated suppression.
Spatial single-cell analysis has shown that C-X-C motif chemokine ligand 13 (CXCL13)-associated immune neighborhoods correlate with benefit from immunotherapy in NSCLC; in animal experiments, supplementation with CXCL13 increased antigen-experienced T cells and enhanced the effect of PD-1 blockade (90). Mature tertiary lymphoid structures (TLSs) are also associated with more favorable immune responses in some patients with NSCLC, whereas their function can be limited when the structures are immature or accompanied by specific myeloid barriers (91). Site-specific evidence that lactate directly determines the maturation of these structures is currently lacking. A testable hypothesis is that lower lactate input within or adjacent to TLSs favors dendritic-cell priming and CD8+ T-cell function, whereas a peripheral belt of high-lactate CAFs or myeloid cells forms a metabolic barrier.
5.5 Primary and metastatic niches
Spatial niches change according to the metastatic site. Single-cell and spatial transcriptomics of lymph-node metastases from lung cancer have shown that tumor immunometabolic programs and cellular neighborhoods are reorganized as metastasis progresses (92). Marked spatiotemporal immune heterogeneity also exists between primary NSCLC and brain metastases (93). Lymph nodes are rich in immune cells and lipid substrates, whereas brain tissue has distinctive lactate shuttles, glial cells, and a blood-brain barrier. The same tumor clone may therefore use different lactate sources and lactylation substrates in these environments.
Within malignant pleural effusion, H3K18la in CAFs promotes FOXO3-dependent CXCL16 expression and recruitment of TNFR2+ regulatory T cells. This stromal-to-immune sequence illustrates how fluid-filled metastatic spaces can establish lactylation networks distinct from those in the primary parenchyma (). Comparisons among primary tumors, pleural effusions, lymph nodes, and brain metastases require paired specimens with spatial information preserved. Paired spatial specimens are therefore preferable for comparisons across metastatic sites.
Metastasis may also rearrange lactate substrates and recipient cells. CAFs or hypoxic tumor cells can serve as the main lactate sources in primary tumors. After entry into a lymph node, the immune-cell-rich and lipid-rich environment changes substrate competition; after entry into brain tissue, the pre-existing lactate shuttle between neurons and glia creates a new metabolic background. The writers, erasers, and target sites retained by tumor cells interact with lactate inputs supplied by the metastatic organ to determine the final Kla landscape. Clonal tracing, spatial metabolomics, and site-specific proteomics in paired patient specimens can distinguish an intrinsic program carried with the clone from a program newly induced by the metastatic organ (94, 95) (TableĀ 3).
5.6 Integrated spatial model
Available lung-cancer evidence supports a spatial model in which hypoxic or glycolytic regions act as lactate sources, whereas oxidative tumor, immune, and stromal compartments serve as recipients or relay zones; validated lactylation mechanisms then stabilize selected malignant and immunosuppressive states (, 96, 97).
The strength of evidence within this model is uneven. Metabolic heterogeneity and lactate utilization in human lung cancer are supported by in vivo tracing. Multiple tumor-cell lactylation pathways have undergone site-specific and functional validation. Intercellular feedback involving macrophages and CAFs is supported by lung cancer models. Some mechanisms involving NK cells, dendritic cells, and neutrophils derive mainly from other tumor types. The principal remaining gap is direct spatial coupling of lactate flux to defined Kla sites within the same lung tumor (98ā100). Future studies should combine isotope tracing, site-resolved proteomics, and cell-specific perturbation in matched lung-cancer tissue to convert spatial association into mechanism (101ā103) (FigureĀ 4).
FigureĀ 4
6 Targeting lactate and lactylation
Lactate transport is currently the most clinically advanced entry point. MCT1 blockade can disrupt lactate-supported oxidative metabolism and metabolic symbiosis (). In small cell lung cancer, the MCT1 inhibitor AZD3965 showed preclinical activity, particularly in MCT4-low or MCT4-negative models (104), while a phase I study in advanced cancers demonstrated target engagement with dose-dependent, largely reversible ocular toxicity (105). These findings establish MCT1 as a druggable target, although they do not prove that efficacy derives from reduced protein lactylation, and MCT4-mediated compensation may limit response.
Upstream lactate supply and lactylation machinery provide additional, mainly preclinical, targets. Inhibition of lactate dehydrogenase A (LDHA) reduces lactate production and suppresses tumor growth in experimental models (106), while catalytic inhibition of p300/CBP is pharmacologically feasible (107) but is not lactylation-specific. In lung cancer, lactylation of programmed death ligand 1 (PD-L1) at K280, hexokinase 2 (HK2) at K873, enolase 1 (ENO1), Mic60, and replication protein A1 (RPA1) at K73 links this modification to immune-checkpoint stability, glycolysis, mitochondrial adaptation, and DNA repair (, ā). These sites provide mechanistic rationale, but site-selective therapeutic strategies remain preclinical.
Combination strategies remain a preclinical research direction. HK2 K873la provides a rationale for testing lactate-axis interventions in cisplatin resistance (). ENO1 lactylation has been linked to osimertinib resistance (), whereas Mic60 lactylation supports EGFR-TKI resistance (). RPA1 K73la provides a site-specific link to radioresistance (). Immune-evasion mechanisms also provide a rationale for testing combinations with checkpoint blockade (). However, these combinations have not been clinically established. A composite biomarker integrating MCT1/MCT4 expression, validated Kla sites, cell identity, and spatial immune context remains hypothesis-generating, and selecting MCT1 versus MCT4 inhibitors according to niche architecture has not been validated in spatial intervention studies. These concepts should therefore guide prospective biomarker and intervention studies rather than current treatment selection.
7 Conclusion
In lung cancer, lactate forms a distributed control layer that couples carbon flux, redox balance, proton handling, and site-specific protein modification across spatially separated cell states. In vivo isotope tracing in fasted mice has shown that circulating lactate contributed more carbon than circulating glucose to TCA-cycle intermediates in genetically engineered lung tumors (). Together with direct analysis of tumor interstitial fluid (108), these findings support a source-to-site view in which regional lactate availability and site-specific lactylation are interpreted within their tissue context.
Current evidence supports a spatially resolved research framework but remains insufficient for clinical stratification. Tumor glycolysis has been associated with poor T-cell infiltration in lung-cancer samples, although lactylation was not established as the causal mediator (109). Future studies should directly couple regional lactate flux with cell-type-specific, site-resolved lactylation and functional perturbation in matched lung-cancer tissues. Prospective validation is required to determine whether these spatial metabolic features can support biomarker development or guide lactate-axis interventions.
Statements
Author contributions
ZL: Conceptualization, Investigation, Data curation, Writing - original draft. CC: Conceptualization, Funding acquisition, Supervision, Writing - review & editing. SW: Data curation, Visualization, Writing - review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. This work was supported by the Jilin Provincial Science and Technology Development Program (Grant No. YDZJ202501ZYTS668). The funder had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Acknowledgments
We thank our colleagues for valuable discussions on lactylation-mediated immune evasion mechanisms. We also thank the reviewers for their critical feedback that improved the manuscript.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Generative AI statement
The author(s) declared that generative AI was used in the creation of this manuscript. ChatGPT (OpenAI; GPT-6; https://chatgpt.com/) was used to assist with language editing, verification and formatting of references, and preparation of author proof corrections. The authors reviewed and revised the resulting material and remain responsible for the accuracy and integrity of the manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisherās note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Abbreviations
CAF, Cancer-associated fibroblast; MCT, Monocarboxylate transporter; EGFR-TKI, Epidermal growth factor receptor tyrosine kinase inhibitor; NK, Natural killer; ENO1, Enolase 1; NSCLC, Non-small cell lung cancer; H3K18la, Histone H3 lysine 18 lactylation; pan-Kla, Pan-lysine lactylation; HK2, Hexokinase 2; PD-1, Programmed cell death protein 1; IGF1R, Insulin-like growth factor 1 receptor; PD-L1, Programmed death ligand 1; Kla, Lysine lactylation; PRC2, Polycomb repressive complex 2; LDH, Lactate dehydrogenase; Treg, Regulatory T cell; LDHA, Lactate dehydrogenase A; YTHDF2, YTH N6-methyladenosine RNA binding protein 2; m6A, N6-methyladenosine.
References
1
HensleyCTFaubertBYuanQLev-CohainNJinEKimJet al. Metabolic heterogeneity in human lung tumors. Cell. (2016) 164:681ā94. doi:Ā 10.1016/j.cell.2015.12.034
2
FaubertBLiKYCaiLHensleyCTKimJZachariasLGet al. Lactate metabolism in human lung tumors. Cell. (2017) 171:358ā371.e9. doi:Ā 10.1016/j.cell.2017.09.019
3
SonveauxPVĆ©granFSchroederTWerginMCVerraxJRabbaniZNet al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest. (2008) 118:3930ā42. doi:Ā 10.1172/jci36843
4
de la Cruz-LópezKGCastro-MuƱozLJReyes-HernĆ”ndezDOGarcĆa-CarrancĆ”AManzo-MerinoJ. Lactate in the regulation of tumor microenvironment and therapeutic approaches. Front Oncol. (2019) 9:1143. doi:Ā 10.3389/fonc.2019.01143
5
ZhangDTangZHuangHZhouGCuiCWengYet al. Metabolic regulation of gene expression by histone lactylation. Nature. (2019) 574:575ā80. doi:Ā 10.1038/s41586-019-1678-1
6
ZhangCZhouLZhangMDuYLiCRenHet al. H3K18 lactylation potentiates immune escape of non-small cell lung cancer. Cancer Res. (2024) 84:3589ā601. doi:Ā 10.1158/0008-5472.can-23-3513
7
TanYTanWLiangYLongYChenSHuQet al. Machine learning-enabled spatial multi-omics uncovers lactate-driven targets and tumor microenvironmental reprogramming in cancer. NPJ Digit Med. (2026) 9:109. doi:Ā 10.1038/s41746-025-02286-7
8
GaoJLiuRHuangKLiZShengXChakrabortyKet al. Dynamic investigation of hypoxia-induced L-lactylation. Proc Natl Acad Sci USA. (2025) 122:e2404899122. doi:Ā 10.1073/pnas.2404899122
9
ThomasCBishopDJLambertKMercierJBrooksGA. Effects of acute and chronic exercise on sarcolemmal MCT1 and MCT4 contents in human skeletal muscles: current status. Am J Physiol Regul Integr Comp Physiol. (2012) 302:R1āR14. doi:Ā 10.1152/ajpregu.00250.2011
10
ZhaoMHuangCYangLPanBYangSChangJet al. SYVN1-mediated ubiquitylation directs localization of MCT4 in the plasma membrane to promote the progression of lung adenocarcinoma. Cell Death Dis. (2023) 14:666. doi:Ā 10.1038/s41419-023-06208-x
11
QianYGalan-CoboAGuijarroIDangMMolkentineDPoteeteAet al. MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma. Cancer Cell. (2023) 41:1363ā1380.e7. doi:Ā 10.1016/j.ccell.2023.05.015
12
HungYPAlbeckJGTantamaMYellenG. Imaging cytosolic NADH-NAD(+) redox state with a genetically encoded fluorescent biosensor. Cell Metab. (2011) 14:545ā54. doi:Ā 10.1016/j.cmet.2011.08.012
13
GoSKramerTTVerhoevenAJOude ElferinkRPJChangJC. The extracellular lactate-to-pyruvate ratio modulates the sensitivity to oxidative stress-induced apoptosis via the cytosolic NADH/NAD+ redox state. Apoptosis. (2021) 26:38ā51. doi:Ā 10.1007/s10495-020-01648-8
14
ShiLSalamonHEugeninEAPineRCooperAGennaroML. Infection with Mycobacterium tuberculosis induces the Warburg effect in mouse lungs. Sci Rep. (2015) 5:18176. doi:Ā 10.1038/srep18176
15
GleesonLESheedyFJPalsson-McDermottEMTrigliaDOāLearySMOāSullivanMPet al. Cutting edge: Mycobacterium tuberculosis induces aerobic glycolysis in human alveolar macrophages that is required for control of intracellular bacillary replication. J Immunol. (2016) 196:2444ā9. doi:Ā 10.4049/jimmunol.1501612
16
YuYHLiaoCCHsuWHChenHJLiaoWCMuoCHet al. Increased lung cancer risk among patients with pulmonary tuberculosis: a population cohort study. J Thorac Oncol. (2011) 6:32ā7. doi:Ā 10.1097/jto.0b013e3181fb4fcc
17
BrennerDRBoffettaPDuellEJBickebƶllerHRosenbergerAMcCormackVet al. Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium. Am J Epidemiol. (2012) 176:573ā85. doi:Ā 10.1093/aje/kws151
18
HuiSGhergurovichJMMorscherRJJangCTengXLuWet al. Glucose feeds the TCA cycle via circulating lactate. Nature. (2017) 551:115ā8. doi:Ā 10.1038/nature24057
19
BrooksGACurlCCLeijaRGOsmondADDuongJJArevaloJA. Tracing the lactate shuttle to the mitochondrial reticulum. Exp Mol Med. (2022) 54:1332ā47. doi:Ā 10.1038/s12276-022-00802-3
20
ZhangDGaoJZhuZMaoQXuZSinghPKet al. Lysine L-lactylation is the dominant lactylation isomer induced by glycolysis. Nat Chem Biol. (2025) 21:91ā9. doi:Ā 10.1038/s41589-024-01680-8
21
GaffneyDOJenningsEQAndersonCCMarentetteJOShiTSchou OxvigAMet al. Non-enzymatic lysine lactoylation of glycolytic enzymes. Cell Chem Biol. (2020) 27:206ā213.e6. doi:Ā 10.1016/j.chembiol.2019.11.005
22
YangYHWangQCKongJYangJTLiuJF. Global profiling of lysine lactylation in human lungs. Proteomics. (2023) 23:e2200437. doi:Ā 10.1002/pmic.202200437
23
ZhuRYeXLuXXiaoLYuanMZhaoHet al. ACSS2 acts as a lactyl-CoA synthetase and couples KAT2A to function as a lactyltransferase for histone lactylation and tumor immune evasion. Cell Metab. (2025) 37:361ā376.e7. doi:Ā 10.1016/j.cmet.2024.10.015
24
GonzattiMBHintzenJCJSharmaINajarMATsusakaTMarcinkiewiczMMet al. Class I histone deacetylases catalyze lysine lactylation. J Biol Chem. (2025) 301:110602. doi:Ā 10.1016/j.jbc.2025.110602
25
BaoQWanNHeZCaoJYuanWHaoHet al. Subcellular proteomic mapping of lysine lactylation. J Am Soc Mass Spectrom. (2024) 35:3221ā32. doi:Ā 10.1021/jasms.4c00366
26
LiXZhangYXuLWangAZouYLiTet al. Ultrasensitive sensors reveal the spatiotemporal landscape of lactate metabolism in physiology and disease. Cell Metab. (2023) 35:200ā211.e9. doi:Ā 10.1016/j.cmet.2022.10.002
27
LiangLZongYHuangJChenYXuNYanPet al. Lactylation stabilizes PD-L1 to promote tumor immune evasion and cell growth. Cell Death Dis. (2026) 17:335. doi:Ā 10.1038/s41419-026-08589-1
28
WuGChenMHeTPanYLiCLiuZet al. Lactylation of CREB is required for FSH-induced proliferation and differentiation of ovarian granulosa cells. Nucleic Acids Res. (2025) 53:gkaf882. doi:Ā 10.1093/nar/gkaf882
29
NiuZChenCWangSLuCWuZWangAet al. HBO1 catalyzes lysine lactylation and mediates histone H3K9la to regulate gene transcription. Nat Commun. (2024) 15:3561. doi:Ā 10.1038/s41467-024-47900-6
30
LiHLiuCLiRZhouLRanYYangQet al. AARS1 and AARS2 sense L-lactate to regulate cGAS as global lysine lactyltransferases. Nature. (2024) 634:1229ā37. doi:Ā 10.1038/s41586-024-07992-y
31
ZongZXieFWangSWuXZhangZYangBet al. Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis. Cell. (2024) 187:2375ā2392.e33. doi:Ā 10.1016/j.cell.2024.04.002
32
Moreno-YruelaCZhangDWeiWBækMLiuWGaoJet al. Class I histone deacetylases (HDAC1-3) are histone lysine delactylases. Sci Adv. (2022) 8:eabi6696. doi: 10.1126/sciadv.abi6696
33
DuRGaoYYanCRenXQiSLiuGet al. Sirtuin 1/sirtuin 3 are robust lysine delactylases and sirtuin 1-mediated delactylation regulates glycolysis. iScience. (2024) 27:110911. doi:Ā 10.1016/j.isci.2024.110911
34
WenTYangLCaiSLiuYFanJWuPet al. SATB2 mediates H3K9 delactylation by recruiting HDAC3 to repress LCN2 and inhibit lung tumor growth and metastasis. Adv Sci (Weinh). (2026) 13:e22996. doi:Ā 10.1002/advs.202522996
35
JiangJHuangDJiangYHouJTianMLiJet al. Lactate modulates cellular metabolism through histone lactylation-mediated gene expression in non-small cell lung cancer. Front Oncol. (2021) 11:647559. doi:Ā 10.3389/fonc.2021.647559
36
LiuMGuLZhangYLiYZhangLXinYet al. LKB1 inhibits telomerase activity resulting in cellular senescence through histone lactylation in lung adenocarcinoma. Cancer Lett. (2024) 595:217025. doi:Ā 10.1016/j.canlet.2024.217025
37
ZhaoSChengJZhouGTaoLXingJLiuLet al. Histone lactylation-driven YTHDF2 promotes non-small cell lung cancer cell glycolysis and stemness by recognizing m6A modification of SFRP2. Biochem Pharmacol. (2025) 240:117097. doi:Ā 10.1016/j.bcp.2025.117097
38
ZhangCDuYJiYYeXLianJZhouHet al. Lactylation-driven KRT19 promotes non-small cell lung cancer progression by suppressing cellular senescence. J Exp Clin Cancer Res. (2026) 45:13. doi:Ā 10.1186/s13046-025-03602-5
39
CaiYLiXZhuSWuHNieJHuangF. Lactate represses MHC-I antigen presentation via H4K5 lactylation-PRC2 in small cell lung cancer subtype A. Int Immunopharmacol. (2026) 170:116125. doi:Ā 10.1016/j.intimp.2025.116125
40
ZhangRLiLYuJ. Lactate-induced IGF1R protein lactylation promotes proliferation and metabolic reprogramming of lung cancer cells. Open Life Sci. (2024) 19:20220874. doi:Ā 10.1515/biol-2022-0874
41
ZhaoZZhangZCaiQYangRLiangHQianBet al. Lactylation increases the stability of RBM15 to drives m6A modification in non-small-cell lung cancer cells. FASEB J. (2025) 39:e70493. doi:Ā 10.1096/fj.202500020rr
42
RaoKZhangXLuoYXiaQJinYHeJ. Lactylation orchestrates ubiquitin-independent degradation of cGAS and promotes tumor growth. Cell Rep. (2025) 44:115441. doi:Ā 10.1016/j.celrep.2025.115441
43
YanFTengYLiXZhongYLiCYanFet al. Hypoxia promotes non-small cell lung cancer cell stemness, migration, and invasion via promoting glycolysis by lactylation of SOX9. Cancer Biol Ther. (2024) 25:2304161. doi:Ā 10.1080/15384047.2024.2304161
44
ChenJZhaoDWangYLiuMZhangYFengTet al. Lactylated apolipoprotein C-II induces immunotherapy resistance by promoting extracellular lipolysis. Adv Sci (Weinh). (2024) 11:e2406333. doi:Ā 10.1002/advs.202406333
45
ZengFWangWLiuPZengQ. Lactylation of HK2 facilitates cisplatin resistance in NSCLC by promoting cell migration, invasion, and glycolysis. Pathol Res Pract. (2026) 279:156349. doi:Ā 10.1016/j.prp.2025.156349
46
GanLSuiQXuMDYangFLiMYuanYet al. A tumor-derived lactate/ENO1 lactylation feedback loop facilitates osimertinib resistance of lung adenocarcinoma. Drug Resist Update. (2026) 85:101346. doi:Ā 10.1016/j.drup.2025.101346
47
ZhengJSheHHanRTangJDouYLuCet al. Dapk2 dysfunction leads to Mic60 lactylation and mitochondrial metabolic reprogramming, promoting lung cancer EGFR-TKI resistance and metastasis. Dev Cell. (2025) 60:3267ā3284.e7. doi:Ā 10.1016/j.devcel.2025.07.014
48
HeJLaiTZhaoYZhouZZhouLTaoDet al. HAT1 functions as a lactyltransferase and mediates RPA1 lactylation to promote DNA repair and radioresistance in lung adenocarcinoma. Cell Death Dis. (2025) 16:851. doi:Ā 10.1038/s41419-025-08113-x
49
HeJLaiTZhouZYangHLeiZZhouLet al. Multiomics profiling reveals the involvement of protein lactylation in nonhomologous end joining pathway conferring radioresistance in lung adenocarcinoma cell. Sci Rep. (2025) 15:24651. doi:Ā 10.1038/s41598-025-09937-5
50
ChenHLiYLiHChenXFuHMaoDet al. NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance. Nature. (2024) 631:663ā9. doi:Ā 10.1038/s41586-024-07620-9
51
PeraltaRMXieBLontosKNieves-RosadoHSpahrKJoshiSet al. Dysfunction of exhausted T cells is enforced by MCT11-mediated lactate metabolism. Nat Immunol. (2024) 25:2297ā307. doi:Ā 10.1038/s41590-024-01999-3
52
ShangXChengBZhangCZhaoCWangRZhangXet al. The LDH-H3K18La-Nur77 axis potentiates immune escape in small cell lung cancer. Adv Sci (Weinh). (2025) 12:e13608. doi:Ā 10.1002/advs.202413608
53
RaychaudhuriDSinghPChakrabortyBHennesseyMTannirAJByregowdaSet al. Histone lactylation drives CD8+ T cell metabolism and function. Nat Immunol. (2024) 25:2140ā51. doi:Ā 10.1038/s41590-024-01985-9
54
WatsonMJVignaliPDAMullettSJOveracre-DelgoffeAEPeraltaRMGrebinoskiSet al. Metabolic support of tumour-infiltrating regulatory T cells by lactic acid. Nature. (2021) 591:645ā51. doi:Ā 10.1038/s41586-020-03045-2
55
KumagaiSKoyamaSItahashiKTanegashimaTLinYTTogashiYet al. Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. Cancer Cell. (2022) 40:201ā218.e9. doi:Ā 10.1016/j.ccell.2022.01.001
56
GuJZhouJChenQXuXGaoJLiXet al. Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells. Cell Rep. (2022) 40:111122. doi: 10.1016/j.celrep.2022.111122
57
WuGChengHYinJZhengYShiHPanBet al. NDRG1-driven lactate accumulation promotes lung adenocarcinoma progression through the induction of an immunosuppressive microenvironment. Adv Sci (Weinh). (2025) 12:e01238. doi:Ā 10.1002/advs.202501238
58
XiongJHeJZhuJPanJLiaoWYeHet al. Lactylation-driven METTL3-mediated RNA m6A modification promotes immunosuppression of tumor-infiltrating myeloid cells. Mol Cell. (2022) 82:1660ā1677.e10. doi:Ā 10.1016/j.molcel.2022.02.033
59
ZhangYShiMLiMQinSMiaoDBaiY. Dynamic single-cell metabolomics reveals cell-cell interaction between tumor cells and macrophages. Nat Commun. (2025) 16:4582. doi:Ā 10.1038/s41467-025-59878-w
60
JinJYanPWangDBaiLLiangHZhuXet al. Targeting lactylation reinforces NK cell cytotoxicity within the tumor microenvironment. Nat Immunol. (2025) 26:1099ā112. doi:Ā 10.1038/s41590-025-02178-8
61
PlebanekMPXueYNguyenYVDeVitoNCWangXHoltzhausenAet al. A lactate-SREBP2 signaling axis drives tolerogenic dendritic cell maturation and promotes cancer progression. Sci Immunol. (2024) 9:eadi4191. doi:Ā 10.1126/sciimmunol.adi4191
62
ZhangBXuAWangHYanWZhangQWangS. MPC-mediated lactate production drives histone lactylation in dendritic cells to affect tumor progression and immunotherapy. Cell Mol Life Sci. (2025) 82:371. doi:Ā 10.1007/s00018-025-05881-9
63
UgoliniADe LeoAYuXScirocchiFLiuXPeixotoBet al. Functional reprogramming of neutrophils within the brain tumor microenvironment by hypoxia-driven histone lactylation. Cancer Discov. (2025) 15:1270ā96. doi:Ā 10.1158/2159-8290.cd-24-1056
64
ZhangCZhouWXuHXuJLiJLiuXet al. Cancer-associated fibroblasts promote EGFR-TKI resistance via the CTHRC1/glycolysis/H3K18la positive feedback loop. Oncogene. (2025) 44:1400ā14. doi:Ā 10.1038/s41388-025-03318-y
65
YeLXiangXWangZZhangSXueQWeiXet al. H3K18 lactylation in cancer-associated fibroblasts drives malignant pleural effusion progression via TNFR2+ Treg recruitment. Exp Mol Med. (2025) 57:2671ā85. doi:Ā 10.1038/s12276-025-01557-3
66
VĆ©granFBoidotRMichielsCSonveauxPFeronO. Lactate influx through the endothelial cell monocarboxylate transporter MCT1 supports an NF-ĪŗB/IL-8 pathway that drives tumor angiogenesis. Cancer Res. (2011) 71:2550ā60. doi:Ā 10.1158/0008-5472.can-10-2828
67
ColegioORChuNQSzaboALChuTRhebergenAMJairamVet al. Functional polarization of tumour-associated macrophages by tumour-derived lactic acid. Nature. (2014) 513:559ā63. doi:Ā 10.1038/nature13490
68
De LeoAUgoliniAYuXScirocchiFScocozzaDPeixotoBet al. Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma. Immunity. (2024) 57:1105ā1123.e8. doi:Ā 10.1016/j.immuni.2024.04.006
69
ZhangHZhangKQiuLYueJJiangHDengQet al. Cancer-associated fibroblasts facilitate DNA damage repair by promoting the glycolysis in non-small cell lung cancer. Biochim Biophys Acta Mol Basis Dis. (2023) 1869:166670. doi:Ā 10.1016/j.bbadis.2023.166670
70
AngelinAGil-de-GómezLDahiyaSJiaoJGuoLLevineMHet al. Foxp3 reprograms T cell metabolism to function in low-glucose, high-lactate environments. Cell Metab. (2017) 25:1282ā1293.e7. doi:Ā 10.1016/j.cmet.2016.12.018
71
ChenYFengZKuangXZhaoPChenBFangQet al. Increased lactate in AML blasts upregulates TOX expression, leading to exhaustion of CD8+ cytolytic T cells. Am J Cancer Res. (2021) 11:5726ā42.
72
Carmona-FontaineCDeforetMAkkariLThompsonCBJoyceJAXavierJB. Metabolic origins of spatial organization in the tumor microenvironment. Proc Natl Acad Sci USA. (2017) 114:2934ā9. doi:Ā 10.1073/pnas.1700600114
73
BalestriniJLChaudhrySSarrazyVKoehlerAHinzB. The mechanical memory of lung myofibroblasts. Integr Biol (Camb). (2012) 4:410ā21. doi:Ā 10.1039/c2ib00149g
74
SattirajuAKangSGiottiBChenZMarallanoVJBruscoCet al. Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression. Immunity. (2023) 56:1825ā1843.e6. doi:Ā 10.1016/j.immuni.2023.06.017
75
HuTAllamMCaiSHendersonWYuehBGaripcanAet al. Single-cell spatial metabolomics with cell-type specific protein profiling for tissue systems biology. Nat Commun. (2023) 14:8260. doi:Ā 10.1038/s41467-023-43917-5
76
WangJSunNKunzkeTShenJZensPPradeVMet al. Spatial metabolomics identifies distinct tumor-specific and stroma-specific subtypes in patients with lung squamous cell carcinoma. NPJ Precis Oncol. (2023) 7:114. doi:Ā 10.1038/s41698-023-00434-4
77
BackmanMStrellCLindbergAMattssonJSMElfvingHBrunnstrƶmHet al. Spatial immunophenotyping of the tumour microenvironment in non-small cell lung cancer. Eur J Cancer. (2023) 185:40ā52. doi:Ā 10.1016/j.ejca.2023.02.012
78
CorbetCBastienEDraouiNDoixBMignionLJordanBFet al. Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects. Nat Commun. (2018) 9:1208. doi:Ā 10.1038/s41467-018-03525-0
79
BoucherYBaxterLTJainRK. Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res. (1990) 50:4478ā84.
80
MuXShiWXuYXuCZhaoTGengBet al. Tumor-derived lactate induces M2 macrophage polarization via the activation of the ERK/STAT3 signaling pathway in breast cancer. Cell Cycle. (2018) 17:428ā38. doi:Ā 10.1080/15384101.2018.1444305
81
SunJFengQHeYWangMWuY. Lactate activates CCL18 expression via H3K18 lactylation in macrophages to promote tumorigenesis of ovarian cancer. Acta Biochim Biophys Sin (Shanghai). (2024) 56:1373ā86. doi:Ā 10.3724/abbs.2024111
82
ChenCGuoQLiuYHouQLiaoMGuoYet al. Single-cell and spatial transcriptomics reveal POSTN+ cancer-associated fibroblasts correlated with immune suppression and tumour progression in non-small cell lung cancer. Clin Transl Med. (2023) 13:e1515. doi:Ā 10.1002/ctm2.1515
83
FanGXieTTangLLiLHanXShiY. The co-location of CD14+APOE+ cells and MMP7+ tumour cells contributed to worse immunotherapy response in non-small cell lung cancer. Clin Transl Med. (2024) 14:e70009. doi:Ā 10.1002/ctm2.70009
84
MonkmanJKilgallonALawlerCTubellezaRAungTNWarrellJHet al. Metabolic characterization of tumor-immune interactions by multiplexed immunofluorescence reveals spatial mechanisms of immunotherapy response in non-small cell lung carcinoma (NSCLC). Nat Commun. (2026) 17:837. doi:Ā 10.1038/s41467-026-68633-8
85
PayenVLMinaEVan HĆ©eVFPorporatoPESonveauxP. Monocarboxylate transporters in cancer. Mol Metab. (2020) 33:48ā66. doi:Ā 10.1016/j.molmet.2019.07.006
86
CaiHChenXLiuYChenYZhongGChenXet al. Lactate activates trained immunity by fueling the tricarboxylic acid cycle and regulating histone lactylation. Nat Commun. (2025) 16:3230. doi:Ā 10.1038/s41467-025-58563-2
87
EnfieldKSSColliverELeeCMagnessAMooreDASivakumarMet al. Spatial architecture of myeloid and T cells orchestrates immune evasion and clinical outcome in lung cancer. Cancer Discov. (2024) 14:1018ā47. doi:Ā 10.1158/2159-8290.cd-23-1380
88
De ZuaniMXueHParkJSDentroSCSeferbekovaZTessierJet al. Single-cell and spatial transcriptomics analysis of non-small cell lung cancer. Nat Commun. (2024) 15:4388. doi:Ā 10.1038/s41467-024-48700-8
89
ChenJHNiemanLTSpurrellMJorgjiVElmelechLRichieriPet al. Human lung cancer harbors spatially organized stem-immunity hubs associated with response to immunotherapy. Nat Immunol. (2024) 25:644ā58. doi:Ā 10.1038/s41590-024-01792-2
90
SorinMKarimiERezanejadMYuMWDesharnaisLMcDowellSACet al. Single-cell spatial landscape of immunotherapy response reveals mechanisms of CXCL13 enhanced antitumor immunity. J Immunother Cancer. (2023) 11:e005545. doi:Ā 10.1136/jitc-2022-005545
91
PeyraudFGuéganJPReyCLaraOOdinODel CastilloMet al. Spatially resolved transcriptomics reveal the determinants of primary resistance to immunotherapy in NSCLC with mature tertiary lymphoid structures. Cell Rep Med. (2025) 6:101934. doi: 10.1016/j.xcrm.2025.101934
92
ZhangYZhuWDengCFuFLiYYeTet al. Single-cell and spatial transcriptome analyses reveal tumor immunometabolism in lymph node metastasis of lung cancer. Cancer Biol Med. (2026). doi:Ā 10.20892/j.issn.2095-3941.2025.0587
93
LiuJSCaiYXHeYZXuJTianSFLiZQ. Spatial and temporal heterogeneity of tumor immune microenvironment between primary tumor and brain metastases in NSCLC. BMC Cancer. (2024) 24:123. doi:Ā 10.1186/s12885-024-11875-w
94
WangCLuoD. The metabolic adaptation mechanism of metastatic organotropism. Exp Hematol Oncol. (2021) 10:30. doi:Ā 10.1186/s40164-021-00223-4
95
DuanHRenJWeiSYangZLiCWangZet al. Integrated analyses of multi-omic data derived from paired primary lung cancer and brain metastasis reveal the metabolic vulnerability as a novel therapeutic target. Genome Med. (2024) 16:138. doi:Ā 10.1186/s13073-024-01410-8
96
ChenJHuangZChenYTianHChaiPShenYet al. Lactate and lactylation in cancer. Signal Transduct Target Ther. (2025) 10:38. doi:Ā 10.1038/s41392-024-02082-x
97
IozzoMPardellaEGiannoniEChiarugiP. The role of protein lactylation: A kaleidoscopic post-translational modification in cancer. Mol Cell. (2025) 85:1263ā79. doi:Ā 10.1016/j.molcel.2025.02.011
98
LiHSunLGaoPHuH. Lactylation in cancer: Current understanding and challenges. Cancer Cell. (2024) 42:1803ā7. doi:Ā 10.1016/j.ccell.2024.09.006
99
JangCChenLRabinowitzJD. Metabolomics and isotope tracing. Cell. (2018) 173:822ā37. doi:Ā 10.1016/j.cell.2018.03.055
100
DonnellanLYoungCSeidelJDPeakeBLauDDeoPet al. An investigation into the differentiation of lactyllysine and carboxyethyllysine peptide modifications by liquid chromatography/mass spectrometry. J Proteome Res. (2026) 25:1601ā10. doi:Ā 10.1021/acs.jproteome.5c00969
101
von der HeydeSRamanNGabeliaNMatias-GuiuXYoshinoTTsukadaYet al. Tumor specimen cold ischemia time impacts molecular cancer drug target discovery. Cell Death Dis. (2024) 15:691. doi:Ā 10.1038/s41419-024-07090-x
102
WangGHeijsBKostidisSMahfouzARietjensRGJBijkerkRet al. Analyzing cell-type-specific dynamics of metabolism in kidney repair. Nat Metab. (2022) 4:1109ā18. doi:Ā 10.1038/s42255-022-00615-8
103
DhainautMRoseSAAkturkGWroblewskaANielsenSRParkESet al. Spatial CRISPR genomics identifies regulators of the tumor microenvironment. Cell. (2022) 185:1223ā1239.e20. doi:Ā 10.1016/j.cell.2022.02.015
104
PolaÅskiRHodgkinsonCLFusiANonakaDPriestLKellyPet al. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer. Clin Cancer Res. (2014) 20:926ā37. doi:Ā 10.1158/1078-0432.ccr-13-2270
105
HalfordSVealGJWedgeSRPayneGSBaconCMSloanPet al. A phase I dose-escalation study of AZD3965, an oral monocarboxylate transporter 1 inhibitor, in patients with advanced cancer. Clin Cancer Res. (2023) 29:1429ā39. doi:Ā 10.1158/1078-0432.ccr-22-2263
106
LeACooperCRGouwAMDinavahiRMaitraADeckLMet al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA. (2010) 107:2037ā42. doi:Ā 10.1073/pnas.0914433107
107
LaskoLMJakobCGEdaljiRPQiuWMontgomeryDDigiammarinoELet al. Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours. Nature. (2017) 550:128ā32. doi:Ā 10.1038/nature24028
108
SullivanMRDanaiLVLewisCAChanSHGuiDYKunchokTet al. Quantification of microenvironmental metabolites in murine cancers reveals determinants of tumor nutrient availability. Elife. (2019) 8:e44235. doi:Ā 10.7554/elife.44235
109
CasconeTMcKenzieJAMbofungRMPuntSWangZXuCet al. Increased tumor glycolysis characterizes immune resistance to adoptive T cell therapy. Cell Metab. (2018) 27:977ā987.e4. doi:Ā 10.1016/j.cmet.2018.02.024
Summary
Keywords
cell-cell interactions, lactate, lung cancer, lysine lactylation, spatial niche, tumor immunometabolism
Citation
Lin Z, Che C and Wang S (2026) Lactylation-mediated remodeling of spatial immunometabolic niches in lung cancer: metabolic origins, cellular interactions, and molecular mechanisms. Front. Oncol. 16:1967572. doi: 10.3389/fonc.2026.1967572
Received
14 August 2026
Revised
09 October 2026
Accepted
11 October 2026
Published
02 November 2026
Volume
16 - 2026
Edited by
Angela M. Otto, Technical University of Munich, Germany
Reviewed by
Tao Jie, Fudan University, China
Liping Zuo, Huazhong University of Science and Technology, China
Updates
Copyright
Ā© 2026 Lin, Che and Wang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Chengri Che, ycrche@ybu.edu.cn
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.